Last reviewed · How we verify
NCT06613230
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
trial in Ovarian Cancer in 490 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Region Skane |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 490 |
| Start date | 1 February 2024 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 2 locations across Sweden |
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Breast Cancer — all drugs for Breast Cancer →
- Lymphoma — all drugs for Lymphoma →
Sponsor
Region Skane — full company profile →
Who can join
Adults 18 to 70, female only, with Ovarian Cancer or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn if so called Volatile Organic Compounds (VOCs) in blood can be used for early diagnosis of ovarian cancer. The main question it aims to answer is: Can OC Detect, a new in vitro diagnostic instrument, distinguish between VOC patterns in blood plasma from women with ovarian cancer (especially in early stage) and VOC patterns in helthy women? Participants are previosuly diagnosed patients with ovarian cancer, who agreed to store their blood samples in biobanks for future medical research purposes. Healthy female blood donors serve as benign control blood samples.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06613230
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Region Skane trials
Trials by the same sponsor.
- NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06613230 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Skane
- Last refreshed: 18 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06613230.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing